Meeting
2022 ASCO Annual Meeting
Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.
Authors
Robin Harrington
Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD
Robin Harrington , Amanda Peach , D'Andra Howell , Biswajit Das , Rini Pauly , Ting-Chia Chang , Jennifer S. LoCoco , Li Chen , Shahanawaz Jiwani , Jennifer Lee , Lisa McShane , Alice P. Chen , Phillip G. Febbo , Traci L. Pawlowski , Naoko Takebe , James V. Tricoli , James H. Doroshow , Paul M. Williams , Chris Alan Karlovich
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3035)
DOI
10.1200/JCO.2022.40.16_suppl.3035
Abstract #
3035
Poster Bd #
27
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Clonal hematopoiesis of indeterminate potential (CHIP) mutations in solid tumor malignancies.
First Author: Madison Conces
Poster
2016 Gastrointestinal Cancers Symposium
Hypermethylated circulating DNA detection using picoliter droplet-based PCR in colorectal cancer.
First Author: Geraldine Perkins
Poster
2023 ASCO Annual Meeting
Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes.
First Author: Pooja Mittal
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
First Author: Jeffrey Lee Jensen